SELEGILINE (ELDEPRYL) FOR PARKINSONS-DISEASE

被引:0
|
作者
WATERS, CH
机构
来源
WESTERN JOURNAL OF MEDICINE | 1991年 / 155卷 / 01期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:68 / 69
页数:2
相关论文
共 50 条
  • [31] TOLERABILITY OF LONG-TERM SELEGILINE THERAPY IN PARKINSONS-DISEASE
    VERMERSCH, P
    PETIT, H
    THERAPIE, 1992, 47 (01): : 75 - 78
  • [32] SELEGILINE IN THE TREATMENT OF PARKINSONS-DISEASE - LONG-TERM EXPERIENCE
    YAHR, MD
    ELIZAN, TS
    MOROS, D
    ACTA NEUROLOGICA SCANDINAVICA, 1989, 80 : 157 - 161
  • [33] LONG-TERM EXPERIENCE WITH SELEGILINE AND LEVODOPA IN PARKINSONS-DISEASE
    LIEBERMAN, A
    NEUROLOGY, 1992, 42 (04) : 32 - 36
  • [34] DOES SELEGILINE MONOTHERAPY IN PARKINSONS-DISEASE ACT BY SYMPTOMATIC OR PROTECTIVE MECHANISMS
    OLANOW, CW
    CALNE, D
    NEUROLOGY, 1992, 42 (04) : 13 - 26
  • [35] DEPRENYL (SELEGILINE) COMBINED WITH LEVODOPA AND A DECARBOXYLASE INHIBITOR IN THE TREATMENT OF PARKINSONS-DISEASE
    PRESTHUS, J
    HAJBA, A
    ACTA NEUROLOGICA SCANDINAVICA, 1983, 68 : 127 - 133
  • [36] CLINICAL-EXPERIENCE ON THE ROLE AND SIGNIFICANCE OF SELEGILINE IN THE TREATMENT OF PARKINSONS-DISEASE
    WORMPETERSEN
    YAHR
    RINNE
    BIRKMAYER
    AQUILONIUS
    PRZUNTEK
    LIEBERMAN
    TETRUD
    KORSGAARD
    LEES
    PRESTHUS
    YOUDIM
    KNOLL
    PAKKENBERG
    ACTA NEUROLOGICA SCANDINAVICA, 1989, 80 : 213 - 219
  • [37] EARLY SELEGILINE THERAPY REDUCES LEVODOPA DOSE REQUIREMENT IN PARKINSONS-DISEASE
    MYLLYLA, VV
    HEINONEN, EH
    VUORINEN, JA
    KILKKU, OI
    SOTANIEMI, KA
    ACTA NEUROLOGICA SCANDINAVICA, 1995, 91 (03): : 177 - 182
  • [39] SELEGILINE USE TO PREVENT PROGRESSION OF PARKINSONS-DISEASE - EXPERIENCE IN 22 DENOVO PATIENTS
    ELIZAN, TS
    YAHR, MD
    MOROS, DA
    MENDOZA, MR
    PANG, S
    BODIAN, CA
    ARCHIVES OF NEUROLOGY, 1989, 46 (12) : 1275 - 1279
  • [40] TOLCAPONE (RO 40-7592) IN COMBINATION WITH SINEMET AND SELEGILINE IN PARKINSONS-DISEASE
    DAVIS, TL
    ROZNOSKI, M
    BURNS, RS
    ANNALS OF NEUROLOGY, 1993, 34 (02) : 300 - 300